FDA Appoints Permanent Leaders for Drug and Biologics Centers
By Editor • September 9, 2026 • 1 min read
The U.S. Food and Drug Administration (FDA) has announced the appointment of permanent directors for its critical centers overseeing drugs and biologics, ending a period of interim leadership.
Michael Davis has been named the director of the Center for Drug Evaluation and Research (CDER), while Karim Mikhail will take the helm at the Center for Biologics Evaluation and Research (CBER). Both officials have been serving in acting capacities for several months.
This move signals a return to stability within the FDA as it continues to navigate the complexities of drug regulation and biologics evaluation amidst an evolving healthcare landscape.
Source: www.statnews.com
#biologics #drug evaluation #FDA #Karim Mikhail #Michael Davis
